Showbox

Overview

Showbox is a Seoul-based film production and distribution company that has dominated the Korean theatrical market in 2026 with a level of market share no single distributor has achieved since before the COVID-19 pandemic. Founded in 1999, the company has cycled through periods of dominance and decline, but its first-half 2026 performance is unprecedented in the modern Korean film market. As of June 18, 2026, Showbox held a 52.3% audience share and approximately 51% of total box office revenue, with four of the top five grossing films in the country this year.

The turnaround is stark. In 2025, none of Showbox's investment or distribution projects ranked in the top 10 Korean box office hits. In late 2023, the company considered withdrawing from the film business entirely. The 2024 occult horror Exhuma (10 million admissions) marked the beginning of a recovery, and the 2026 slate has delivered four consecutive hits that cleared their break-even points: If We, The Man Who Lives with the King, Salmokji, and Gunchae. This run has put Showbox at the center of the Korean film industry's strongest first quarter since 2020, with Korean productions claiming 73.4% of revenue in Q1 2026, up from 53.5% a year earlier.

For Korean filmmakers and international producers seeking Korean theatrical distribution, Showbox has proven it can open films across genres and audience demographics, from period drama to horror to zombie thriller. The company's 2026 slate demonstrates a strategy of differentiating audience bases by title rather than relying on a single demographic.

The 2026 Box Office Run

Showbox's first-half 2026 performance is built on four films, each targeting a different audience segment:

The Man Who Lives with the King (released February 4, 2026) is the standout. Directed by Jang Hang-jun and starring Yoo Hae-jin and Park Ji-hoon, this period drama about a deposed king and a village headman drew 16,898,674 admissions and generated approximately 163 billion won in revenue. It ranks second all-time in admissions and first all-time in revenue among all films released domestically in Korea. It surpassed Exhuma to become Showbox's biggest hit ever and the company's first title to cross $100 million in box office revenue. The film crossed 10 million admissions on March 6, its 31st day in theaters, and continued drawing for over 60 days.

Gunchae (released May 21, 2026), directed by Yeon Sang-ho (Train to Busan) and starring Jun Ji-hyun in her first big-screen role in 11 years, recorded 5,309,632 admissions and approximately 56 billion won in revenue through late June. The zombie thriller was invited to the Midnight Screening section at the 79th Cannes Film Festival and was pre-sold to 124 countries before its domestic release. In Malaysia, it grossed 7 million ringgit in its first three days, surpassing the final box office total of the 2024 hit The Grave. North American distributor Well Go USA cited Yeon's track record as the basis for their acquisition. The film's break-even point was set at 3 million admissions, reflecting casting costs and the CG work required for the zombie sequences. It cleared break-even in 10 days.

Salmokji (released April 8, 2026) is a horror film about a road-view shooting crew that encounters something in a reservoir. Starring Kim Hye-yoon and Lee Jong-won, the film drew 3,240,342 admissions and approximately 33.3 billion won. It surpassed A Tale of Two Sisters (2003) to become the all-time top-grossing Korean horror film, a record that had stood for over 20 years. Its break-even point was approximately 800,000 admissions, which it reached in seven days, the fastest break-even for any 2026 Korean release at that point.

If We (released December 31, 2025) is a romance starring Gu Kyo-hwan and Moon Ga-young, directed by Kim Do-young. It recorded 2.47 million admissions and approximately 24.4 billion won, surpassing its break-even point of 1.1 million admissions. For a straight romance, a genre considered difficult to sell in the Korean market, this performance was notable. The film topped daily charts over the New Year holiday, edging out James Cameron's Avatar: Fire and Ash.

Competitive Landscape

Showbox's 2026 dominance has come at the expense of competitors who have struggled. CJ ENM, typically the largest Korean distributor, had no commercial film releases in the first half of 2026. NEW released Ryoo Seung-wan's blockbuster HUMINT during the Lunar New Year holiday, but it stopped at 1.98 million admissions, failing to surpass its 4 million break-even point. Lotte Entertainment released Heartman and Wild Thing with weak results. Plus M Entertainment released Project Y and Eternal with similarly modest performance. The only non-Showbox title in the top five was Sony Pictures Korea's Project Hail Mary, which drew 2,903,134 admissions.

This competitive vacuum has amplified Showbox's market share, but the company's performance is not merely a function of competitor weakness. Showbox invested aggressively in projects that other distributors had passed on or halted. The Man Who Lives with the King was a project that a major distributor had advanced through development before halting it. Production company Ondaworks then took it over, and Showbox joined as the main investor after evaluating the script's quality. This investment-first approach, rather than waiting for finished films, has given Showbox control over projects that competitors underestimated.

Upcoming Slate

Showbox's 2026 slate continues with Blizzard, a psychological thriller set at an isolated train station buried under heavy snow, starring Kim Yoon-seok and Gu Kyo-hwan, directed by Hong Ui-jeong and Park Sun-woo. The company is also handling international sales for Gunchae across 124 territories, with releases scheduled in Taiwan, Malaysia, France, Singapore, the Philippines, Australia, New Zealand, and North America (August 28 via Well Go USA). A Japanese release is scheduled for 2027.

What Filmmakers Should Know

For Korean filmmakers with prestige commercial productions, Showbox is currently the most successful domestic distribution contact. The company's 2026 track record demonstrates an ability to open films across genres: period drama, horror, zombie thriller, and romance. Showbox differentiates audience bases by title, targeting teens through 30s for horror (Salmokji), 20s through 40s for romance (If We), and all generations for period drama (The Man Who Lives with the King).

For international co-productions involving Korean talent or Korean subjects, Showbox's international relationships provide pathways to Korean theatrical distribution alongside international sales support. The Gunchae pre-sale to 124 countries demonstrates the company's ability to leverage Korean domestic success into international deals, particularly for genre films with established director brands.

Showbox's investment model means the company gets involved at the development and financing stage, not just as a finished-film distributor. Filmmakers seeking Showbox involvement should approach the company with projects in development, not completed films. The company evaluates scripts for completeness and commercial potential, and its investment committee makes decisions based on projected break-even points relative to casting, production budget, and genre expectations.

Quick Reference

• Founded: 1999
• Location: Seoul, South Korea
• 2026 market share: 52.3% audience share, ~51% revenue share (as of June 2026)
• 2026 top hit: The Man Who Lives with the King (16.9 million admissions, 163 billion won)
• All-time record: First Korean distributor to cross $100 million box office revenue on a single title
• 2026 hits: If We, The Man Who Lives with the King, Salmokji, Gunchae (all cleared break-even)
• Break-even benchmarks: 800,000 admissions (horror), 1.1 million (romance), 3 million (zombie thriller with CG)
• Competitors: CJ ENM, NEW, Lotte Entertainment, Plus M Entertainment
• Investment model: Development-stage investment, not finished-film pickup
• International sales: Gunchae pre-sold to 124 countries

Example Titles They've Released

Showbox's 2026 slate delivered four consecutive hits that cleared their break-even points: The Man Who Lives with the King (16.9 million admissions, 163 billion won, second all-time in admissions and first all-time in revenue among domestic Korean releases, surpassed Exhuma to become Showbox's biggest hit ever and first title to cross $100 million), Gunchae (5.3 million admissions, 56 billion won, directed by Yeon Sang-ho of Train to Busan, starring Jun Ji-hyun, invited to Cannes Midnight Screening, pre-sold to 124 countries), Salmokji (3.2 million admissions, 33.3 billion won, all-time top-grossing Korean horror film surpassing A Tale of Two Sisters which had held the record for over 20 years), and If We (2.47 million admissions, 24.4 billion won, romance starring Gu Kyo-hwan and Moon Ga-young). Historic Showbox releases include The Host (2006, Bong Joon-ho), Snowpiercer (2014, Bong Joon-ho), and Exhuma (2024, 10 million admissions). Upcoming: Blizzard (psychological thriller starring Kim Yoon-seok and Gu Kyo-hwan).

Deal Structure Reputation

Showbox operates an investment-first model, getting involved at the development and financing stage rather than waiting for finished films. The company evaluates scripts for completeness and commercial potential, and its investment committee makes decisions based on projected break-even points relative to casting, production budget, and genre expectations. Break-even benchmarks from the 2026 slate: 800,000 admissions for horror (Salmokji), 1.1 million for romance (If We), 3 million for zombie thriller with CG (Gunchae). The Man Who Lives with the King was a project that a major distributor had advanced through development before halting it; production company Ondaworks then took it over, and Showbox joined as the main investor after evaluating the script's quality. This investment-first approach has given Showbox control over projects that competitors underestimated. The company also handles international sales, with Gunchae pre-sold to 124 countries before its domestic release.

Typical Acquisition Profile

For Korean filmmakers with prestige commercial productions, Showbox is currently the most successful domestic distribution contact. The company's 2026 track record demonstrates an ability to open films across genres: period drama, horror, zombie thriller, and romance. Showbox differentiates audience bases by title, targeting teens through 30s for horror (Salmokji), 20s through 40s for romance (If We), and all generations for period drama (The Man Who Lives with the King). For international co-productions involving Korean talent or Korean subjects, Showbox's international relationships provide pathways to Korean theatrical distribution alongside international sales support. Showbox does not accept open submissions for finished films; filmmakers should approach the company with projects in development. The company attends Cannes Marche du Film and other major markets for both acquiring international content and selling Korean productions internationally.

Watch: Trailers and Behind the Scenes

See Also

For the Busan International Film Festival as the primary Korean industry event, see the Film Festivals Directory. To model the revenue from a Korean theatrical release against international pre-sales, use the Revenue Forecast Calculator. To compare Showbox's investment model against other distributor approaches, use the Distributor Comparison Tool.